|
A
Mirage No More
Venturing into the Gulf pharma sector is no easy task, especially
since complicated regulations may prove to be a major stumbling
block. However, early movers have played their cards well
and are poised to reap a bountiful harvest. Manjusha Morgaonkar
analyses the sector
Emcure's
launches new oncology facility
Emcure Pharmaceuticals has launched a new oncology plant at
Hinjwadi, Pune. The facility is spread over an area of 70,000
sq ft. Emcure's total investment for the oncology formulations
facility and API facility exceeds $25 million.
'Pharmerging
markets will be equal to the top five European markets'
With Indian pharmaceutical market depending heavily on brand
extensions rather than new molecules to fuel growth, Shailesh
Gadre, Managing Director, ORG IMS, speaks to Viveka Roychowdhury
about the promise of pharmerging markets
Growththe
organic way
The challenge is doing things differently and yet getting
similar results. This is the mantra that MakroCare, a contract
research organisation (CRO) chants. Arshiya Khan analyses
the CRO's growth
Arch
Pharmalabs acquires majority stake in Benzochem Lifesciences
Arch Pharmalabs has acquired a majority stake in Benzochem
Lifesciences for an undisclosed amount. Benzochem is a privately
held company, engaged in the manufacture of API and intermediates
in the oncology and anti-malarials space.
Sanofi
Pasteur to donate H5N1 vaccine to WHO
Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group,
will donate 60 million doses of H5N1 vaccine to the World
Health Organization (WHO) over three years for the establishment
of an H5N1 vaccine global stockpile.
Dishman's
new plant in Shanghai
Dishman Pharmaceuticals is ready for its first international
foray through the organic route.
Suven
initiates Phase I clinical trials in Europe
Suven has commenced phase I clinical trials of SUVN-502, a
potent, safe, highly selective, brain penetrant and orally
active antagonist at a nonperipheral, CNS receptor site 5-HT6,
intended for the symptomatic treatment of Alzheimer's disease
and other disorders of memory and cognition like attention
deficient hyperactivity, Parkinsons, schizophrenia.
Gennova
Biopharmaceuticals, collaborates with PATH MVI
Gennova Biopharmaceuticals Ltd (GBL) is collaborating with
the PATH Malaria Vaccine Initiative (MVI) to create a dedicated
malaria vaccine manufacturing facility.
Lupin
receives US FDA approval
Lupin's subsidiary in the US, Lupin Pharmaceuticals Inc (LPI)
has received tentative approval for the Abbreviated New Drug
Application (ANDA) for Escitalopram Oxalate tablets 10 mg
and 20 mg from the US Food and Drug Administration (US FDA).
IPCA-Ranbaxy
alliance receives US FDA approval
Ipca Laboratories (Ipca) had earlier announced strategic alliance
with Ranbaxy Pharamceuticals (Ranbaxy) based in Jacksonville,
Florida (USA), a wholly owned subsidiary of Ranbaxy Laboratories
Ltd (RLL).
Sandu
Pharma's geriatric pain management drug in phase II clinical
trials
Mumbai-based Sandu Pharmaceuticals is developing a new drug
for geriatric pain management.
Virtual
R&D to increase innovation and reduce commercial deficit,
by 2020
By 2020, pharma R&D process may be shortened by two-thirds,
success rates may dramatically increase, and clinical trial
costs could be cut substantially, according to a research
report by PriceWaterhouseCoopers, entitled Pharma 2020: Virtual
R&D, which path will you take?
Intas
Biopharma acquires biologics unit in US
Intas Biopharmaceuticals Limited (IBPL) has acquired US-based
biotechnology corporation, Biologics Process Development (BPD),
based in Poway, California for an undisclosed amount.
Pre
Events
Burrill
India life sciences meet
The 3rd Annual Burrill India Life Sciences Meeting held on
the 15 June 2008, at the Omni in San Diego, a day prior to
Bio 2008 was a resounding success.
CII
facilitates business response to HIV/AIDS
Aseminar on 'HIV/AIDSBusiness Response to Prevention
Care and Treatmentwas organised by Confedera-tion of
Indian Industry (CII) under the aegis of projectAccess
to Care and Treatmentin Mumbai.
|